Tumor protein p53-inducible protein 11 (TP53I11)

TP53I11 (Tumor protein p53-inducible protein 11) is a 189-amino acid, 21 kDa protein encoded by the TP53I11 gene, primarily classified as a non-receptor, non-enzyme protein induced by the tumor suppressor p53[1]. Its best-known biological roles are negative regulation of cell proliferation and promotion of apoptotic pathways[2][3][4]. TP53I11 regulates endoplasmic reticulum calcium homeostasis, and its overexpression inhibits cancer cell proliferation, while knockdown accelerates growth[2]. It acts downstream of multiple microRNAs, which either suppress or enhance its function, depending on tissue context. TP53I11 is upregulated by the chemotherapeutic agent doxorubicin, and this upregulation is associated with increased ER Ca(2+) accumulation and inhibition of cancer cell proliferation[2]. High TP53I11 expression is typically tumor-suppressive in breast and liver cancers, but may correlate with poor prognosis in gastric cancer, emphasizing its tissue-specific function[2]. The protein is expressed at variable levels in the cytoplasm across most human tissues[6]. Its therapeutic modulation is being studied for cancer intervention, especially in connection with ER Ca(2+) regulation and cell proliferation inhibition[2].

Other names

PIG11p53-induced gene 11 proteintumour protein p53 inducible protein 11TP53I11

Chemotherapeutic agents like doxorubicin can increase ER Ca(2+) levels and inhibit cancer cell proliferation by upregulating TP53I11. Curcumin may mediate anti-tumor effects at least partly via TP53I11 upregulation.